Om P. Ganda, MD


Clinical Evidence Supporting Cardiovascular and Renal Indications in SGLT2 Inhibitors and GLP-1 Receptor Agonists

August 20, 2021

Om P. Ganda, MD, provides an overview of the clinical trials supporting the use of SGLT2 inhibitors and GLP-1 receptor agonists in cardiovascular and renal indications, and Jeffrey Turner, MD, comments on the kidney disease outcome measures of these trials.

Multisystem Impact of SGLT2 Inhibitors in Cardiorenal Metabolic Syndrome

August 18, 2021

Jeffrey Turner, MD, discusses the discovery of cardiovascular and renal benefits in SGLT2 inhibitors, and Nihar R. Desai, MD, MPH, provides insight into the role of SGLT2 inhibitors in the four pillars of heart failure.